Groen HJM - Search Results

1

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.

Huber RM, Hansen KH, Paz-Ares Rodríguez L, West HL, Reckamp KL, Leighl NB, Tiseo M, Smit EF, Kim DW, Gettinger SN, Hochmair MJ, Kim SW, Langer CJ, Ahn MJ, Kim ES, Kerstein D, Groen HJM, Camidge DR. Huber RM, et al. Among authors: groen hjm. J Thorac Oncol. 2020 Mar;15(3):404-415. doi: 10.1016/j.jtho.2019.11.004. Epub 2019 Nov 19. J Thorac Oncol. 2020. PMID: 31756496 Free article. Clinical Trial.

2

Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer.

Groen HJ, Smit EF, Haaxma-Reiche H, Postmus PE. Groen HJ, et al. Eur J Cancer. 1993;29A(12):1696-9. doi: 10.1016/0959-8049(93)90107-q. Eur J Cancer. 1993. PMID: 7691116

3

Surgical resection for small cell carcinoma of the lung: a retrospective study.

Smit EF, Groen HJ, Timens W, de Boer WJ, Postmus PE. Smit EF, et al. Thorax. 1994 Jan;49(1):20-2. doi: 10.1136/thx.49.1.20. Thorax. 1994. PMID: 8153935 Free PMC article.

4

Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIB-IV.

Bakker M, Groen HJ, Smit EF, Smeets J, Riggi M, Postmus PE. Bakker M, et al. Br J Cancer. 1995 Dec;72(6):1547-50. doi: 10.1038/bjc.1995.545. Br J Cancer. 1995. PMID: 8519675 Free PMC article. Clinical Trial.

5

Pharmacokinetics and scintigraphy of indium-111-DTPA-MOC-31 in small-cell lung carcinoma.

Kosterink JG, de Jonge MW, Smit EF, Piers DA, Kengen RA, Postmus PE, Shochat D, Groen HJ, The HT, de Leij L. Kosterink JG, et al. J Nucl Med. 1995 Dec;36(12):2356-62. J Nucl Med. 1995. PMID: 8523132 Free article.

6

New prognostic factors in resectable non-small cell lung cancer.

Smit EF, Groen HJ, Splinter TA, Ebels T, Postmus PE. Smit EF, et al. Thorax. 1996 Jun;51(6):638-46. doi: 10.1136/thx.51.6.638. Thorax. 1996. PMID: 8693450 Free PMC article. Review. No abstract available.

7

Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines.

Bakker M, Renes J, Groenhuijzen A, Visser P, Timmer-Bosscha H, Müller M, Groen HJ, Smit EF, de Vries EG. Bakker M, et al. Int J Cancer. 1997 Nov 4;73(3):362-6. doi: 10.1002/(sici)1097-0215(19971104)73:3<362::aid-ijc10>3.0.co;2-f. Int J Cancer. 1997. PMID: 9359483

8

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.

Smit EF, Fokkema E, Biesma B, Groen HJ, Snoek W, Postmus PE. Smit EF, et al. Br J Cancer. 1998;77(2):347-51. doi: 10.1038/bjc.1998.54. Br J Cancer. 1998. PMID: 9461009 Free PMC article. Clinical Trial.

9

Effects of gemcitabine on renal function in patients with non-small cell lung cancer.

Gietema JA, Groen HJ, Meijer S, Smit EF. Gietema JA, et al. Eur J Cancer. 1998 Jan;34(1):199-202. doi: 10.1016/s0959-8049(97)00354-7. Eur J Cancer. 1998. PMID: 9624259

10

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule.

Groen HJ, Fokkema E, Biesma B, Kwa B, van Putten JW, Postmus PE, Smit EF. Groen HJ, et al. J Clin Oncol. 1999 Mar;17(3):927-32. doi: 10.1200/JCO.1999.17.3.927. J Clin Oncol. 1999. PMID: 10071286 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

459 results

Search Page

Filters